AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

Abbott Laboratories stock is trading close to analysts’ consensus target, backed by strong Q2 diagno

The settlement resolves allegations that the products caused gastrointestinal disease among infants.

In August 2026, Abbott Laboratories agreed to pay approximately US$670 million to resolve the Gill case and around 2,000 additional necrotizing enterocolitis-related claims tied to its preterm infant formulas, without admitting liability and following several favorable court rulings for formula manufacturers. This large settlement trims a single, very large jury award while providing greater clarity on Abbott’s remaining infant-formula litigation exposure and case mix. We’ll now explore how...

Legal settlement reshapes the risk picture for Abbott Laboratories stock Abbott Laboratories (ABT) has agreed to resolve the Gill case and about 2,000 related necrotizing enterocolitis claims linked to its preterm infant formulas for roughly US$670 million, reframing investors’ view of its legal overhang. See our latest analysis for Abbott Laboratories. Recent trading shows momentum building in Abbott Laboratories stock, with the share price up 13.18% over 30 days and 33.44% over 90 days,...

These two high-quality dividend payers have had very different fortunes recently.

Abbott Laboratories stock is trading in the mid-$110s as of August 22, 2026, with fresh Q2 earnings,

Abbott Laboratories acordó pagar 670 millones de dólares para resolver aproximadamente 2.000 demandas que alegaban que sus fórmulas a base de leche de vaca de uso hospitalario causaban necrosis...

Las acciones de Abbott Laboratories están respaldadas por un ritmo del segundo trimestre de 2026, una orientación más alta y un precio de apertura de 114,16 dólares.